Recent investigations have focused on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and DA neurotransmission. While GCGR activators are commonly employed for managing type 2 T2DM, their potential consequences on motivation circuits, spe